HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,860,000 shares, a decrease of 5.6% from the August 31st total of 1,970,000 shares. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 10.2% of the shares of the company are short sold.

HilleVax Stock Performance

Shares of NASDAQ HLVX remained flat at $1.76 during trading on Monday. The stock had a trading volume of 83,530 shares, compared to its average volume of 486,506. The stock has a market capitalization of $87.51 million, a P/E ratio of -0.53 and a beta of 0.81. The stock has a fifty day moving average price of $1.80 and a 200-day moving average price of $8.94. HilleVax has a twelve month low of $1.55 and a twelve month high of $20.22.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). Research analysts expect that HilleVax will post -2.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Maven Securities LTD acquired a new position in HilleVax in the 2nd quarter valued at about $217,000. Point72 Asset Management L.P. acquired a new stake in HilleVax in the second quarter valued at $6,960,000. Algert Global LLC acquired a new position in HilleVax during the second quarter worth about $519,000. Frazier Life Sciences Management L.P. grew its holdings in shares of HilleVax by 8.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company’s stock worth $153,523,000 after acquiring an additional 835,590 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new position in shares of HilleVax during the 2nd quarter worth $3,844,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Leerink Partners lowered shares of HilleVax from an “outperform” rating to a “market perform” rating and cut their target price for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Stifel Nicolaus cut HilleVax from a “buy” rating to a “hold” rating and dropped their target price for the company from $34.00 to $3.00 in a research report on Tuesday, July 9th. Guggenheim cut HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of HilleVax in a research report on Monday, August 12th. Finally, Leerink Partnrs lowered HilleVax from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.20.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.